Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1282-1287, 2006
DOI: 10.2337/dc05-1879
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnett, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnett, A. H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Emerging Treatments and Technologies
Original Article

An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea

Anthony H. Barnett, BSC, MD, FRCP1, Manfred Dreyer, MD2, Peter Lange, MD3, Marjana Serdarevic-Pehar4 on behalf of the Exubera Phase III Study Group

1 University of Birmingham and Heart of England National Health Service Foundation Trust (Teaching), Birmingham, U.K.
2 Department of Diabetes and Metabolism, Bethanien Krankenhaus, Hamburg, Germany
3 Department of Respiratory Medicine, Hvidovre University Hospital, Hvidovre, Denmark
4 Department of Respiratory Medicine, Pfizer, Sandwich, U.K.

Address correspondence and reprint requests to A.H. Barnett, Undergraduate Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK. E-mail: anthony.barnett{at}heartofengland.nhs.uk

OBJECTIVE—To compare the efficacy and safety profile of adding inhaled human insulin (INH; Exubera) or metformin to sulfonylurea monotherapy in patients with poorly controlled type 2 diabetes.

RESEARCH DESIGN AND METHODS—We performed an open-label, parallel, 24-week, multicenter trial. At week –1, patients uncontrolled on sulfonylurea monotherapy were divided into two HbA1c (A1C) arms: ≥8 to ≤9.5% (moderately high) and >9.5 to ≤12% (very high). Patients were randomized to adjunctive premeal INH (n = 225) or metformin (n = 202). The primary efficacy end point was change in A1C from baseline.

RESULTS—In the A1C >9.5% arm, INH demonstrated a significantly greater reduction in A1C than metformin. Mean adjusted changes from baseline were –2.17 and –1.79%, respectively; between-treatment difference was –0.38% (95% CI –0.63 to –0.14, P = 0.002). In the A1C ≤9.5% arm, mean adjusted A1C changes were –1.94 and –1.87%, respectively (–0.07% [–0.33 to 0.19], P = 0.610), consistent with the noninferiority criterion. Hypoglycemia (events/subject-month) was greater in the INH (0.33) than in the metformin (0.15) group (risk ratio 2.16 [95% CI 1.67–2.78]), but there were no associated discontinuations. Other adverse events, except increased cough in the INH group, were similar. At week 24, changes in pulmonary function parameters were small and comparable between groups. Insulin antibody binding increased more with INH but did not have any associated clinical manifestations.

CONCLUSIONS—In patients with type 2 diabetes poorly controlled on a sulfonylurea (A1C >9.5%), the addition of premeal INH significantly improves glycemic control compared with adjunctive metformin and is well tolerated.

Abbreviations: ADA, American Diabetes Association • DLco, carbon monoxide transfer factor • FEV1, forced expiratory volume in 1 s • INH, inhaled human insulin


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Find additional patient-related information at:

Inhaled Insulin Safely Improves Blood Glucose Control in Patients With Type 2 Diabetes


This article has been cited by other articles:


Home page
 Diabetes CareHome page
J. Rosenstock, W. T. Cefalu, P. A. Hollander, A. Belanger, F. G. Eliaschewitz, J. L. Gross, S. S. Klioze, L. B. St. Aubin, H. Foyt, M. Ogawa, et al.
Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes
Diabetes Care, September 1, 2008; 31(9): 1723 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. B. Drummond, P. F. Schwartz, W. T. Duggan, J. G. Teeter, R. J. Riese, R. C. Ahrens, R. O. Crapo, R. D. England, N. R. MacIntyre, R. L. Jensen, et al.
Intersession Variability in Single-Breath Diffusing Capacity in Diabetics without Overt Lung Disease
Am. J. Respir. Crit. Care Med., August 1, 2008; 178(3): 225 - 232.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. Ceglia, J. Lau, and A. G. Pittas
Effect of Inhaled Insulin on Fasting and Postprandial Plasma Glucose
Ann Intern Med, June 5, 2007; 146(11): 821 - 822.
[Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S. Ghosh and A. Collier
Inhaled insulins
Postgrad. Med. J., March 1, 2007; 83(977): 178 - 181.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. T. McMahon and R. A. Arky
Inhaled Insulin for Diabetes Mellitus
N. Engl. J. Med., February 1, 2007; 356(5): 497 - 502.
[Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Exubera: inhaled insulin for diabetes
DTB, January 1, 2007; 45(1): 5 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
Y. C Kudva and A. Basu
Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus
Evid. Based Med., December 1, 2006; 11(6): 176 - 176.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. Ceglia, J. Lau, and A. G. Pittas
Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
Ann Intern Med, November 7, 2006; 145(9): 665 - 675.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group
An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Meformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea: Response to Mikhail and Cope
Diabetes Care, October 1, 2006; 29(10): 2333 - 2334.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
N. Mikhail and D. Cope
An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Meformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea: Response to Barnett et al.
Diabetes Care, October 1, 2006; 29(10): 2332 - 2333.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. H. Barnett, M. Dreyer, P. Lange, M. Serdarevic-Pehar, and on behalf of the Exubera Phase III Study Group
An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin
Diabetes Care, August 1, 2006; 29(8): 1818 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Inhaled Insulin vs. Metformin for Type 2 Diabetes
Journal Watch (General), July 25, 2006; 2006(725): 3 - 3.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.